Preclinical evaluation of the potential PARP-imaging probe [carbonyl-11C]DPQ
Although [carbonyl-<sup>11</sup>C]DPQ demonstrated metabolic stability and specific binding in vitro, suboptimal tumour-targeting properties and pronounced liver metabolism were observed in ovo. Therefore, further animal experiments with mammalian models were not indicated.
Authors
- Marius Ozenil (ORCID: https://orcid.org/0000-0001-6369-6613)
- Joachim Friske (ORCID: https://orcid.org/0000-0002-1830-8113)
- Markus Mitterhauser (ORCID: https://orcid.org/0000-0003-3173-5272)
- Victoria Weissenböck
- Theresa Balber (ORCID: https://orcid.org/0000-0002-8154-5680)
- Verena Pichler (ORCID: https://orcid.org/0000-0003-4544-2438)
- Katarína Benčurová (ORCID: https://orcid.org/0000-0001-6762-0528)
- Cécile Philippe (ORCID: https://orcid.org/0000-0002-7203-7174)
- Lukas Kogler
- Marcus Hacker (ORCID: https://orcid.org/0000-0002-4222-4083)
Institutions
- University of Vienna (AT)
- Center For Biomarker Research In Medicine (AT)
- Medical University of Vienna (AT)
Publication Details
- Journal
- EJNMMI Radiopharmacy and Chemistry
- Published
- 2025-01-10
- DOI
- https://doi.org/10.1186/s41181-024-00323-6
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Universität Wien
- Österreichische Forschungsförderungsgesellschaft
- Medizinische Universität Wien